Neuland Laboratories Q1 Results Revenue Reaches ₹43,960.17 Lakhs, Net Profit at ₹9,787.27 Lakhs

Neuland Laboratories Q1 Results 2024 - 2025: Neuland Laboratories announced their Q1 financial results on August 1, 2024, showing a solid performance with significant growth. For the quarter ending June 30, 2024, the company reported a revenue increase of 14.2% compared to the previous quarter (Q4 2023).

This growth reflects a positive shift in their operations and market demand. Notably, their revenue from operations rose from ₹38,500.97 lakhs in Q4 2023 to ₹43,960.17 lakhs in Q1 2024, demonstrating a strong quarter-over-quarter (QoQ) improvement.

In terms of profitability, Neuland Laboratories saw a 45% increase in profit before tax (PBT) from ₹9,220.20 lakhs in Q4 2023 to ₹12,984.20 lakhs in Q1 2024. This rise in PBT highlights their effective cost management and operational efficiency.

The company’s net profit also grew significantly by 44.7% QoQ, reaching ₹9,787.27 lakhs from ₹6,756.19 lakhs in the previous quarter. Overall, these Q1 results reflect Neuland’s robust financial health and its ability to capitalize on market opportunities, setting a positive tone for the rest of the fiscal year.

For More Q1 results check our Twitter Page

Neuland Laboratories Q1 Results 2024 - 2025

Here’s a summary of Neuland Laboratories’ financial performance for Q1 2024 - 2025:

Source: Click Here

Neuland Laboratories Current Market Overview

Neuland Laboratories is currently trading at ₹12,565, down by 1.04% from its previous value. The company has a market capitalization of ₹16,121 crore and its stock has ranged between ₹3,522 and ₹13,248. With a price-to-earnings ratio of 50.3, Neuland Laboratories shows strong profitability.

The book value of the stock is ₹1,000, and it offers a small dividend yield of 0.11%. The company has impressive financial metrics with a return on capital employed (ROCE) of 33.3% and a return on equity (ROE) of 26.4%.

Quarterly Results

Here is a summary of Neuland Laboratories' quarterly results for the periods ending December 2023, March 2024, and June 2024:

About Neuland Laboratories

Neuland Laboratories is a global company that specializes in developing and manufacturing complex active pharmaceutical ingredients (APIs) for the biotechnology and pharmaceutical industries. With over 40 years of experience, Neuland focuses on creating small molecules and peptides for clinical trials and commercial production.

They are known for their commitment to high-quality standards and efficient processes, helping their clients bring innovative medicines to market. The company operates with a strong emphasis on integrating best practices and delivering superior results throughout the product lifecycle.

Check our website for more Q1 results.